ASX - By Stock
|
LTP |
Re:
Ann: Trading Halt
|
|
Tym1ng
|
22 |
5.9K |
4 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
22
|
5.9K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
5 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
476
|
108K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
2 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
476
|
108K
|
2
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Trading Halt
|
|
Tym1ng
|
22 |
5.9K |
4 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
22
|
5.9K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
10 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
476
|
108K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
14 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
476
|
108K
|
14
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
6 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
109
|
29K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
10 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
476
|
108K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
Tym1ng
|
476 |
108K |
12 |
01/06/24 |
01/06/24 |
ASX - By Stock
|
476
|
108K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix and Taiba enter into License Agreement for DMX-200
|
|
Tym1ng
|
152 |
57K |
13 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
152
|
57K
|
13
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
3 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
109
|
29K
|
3
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
4 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
109
|
29K
|
4
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
2 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
109
|
29K
|
2
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
5 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
109
|
29K
|
5
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
1 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
109
|
29K
|
1
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
2 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
109
|
29K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
14 |
5.3K |
9 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
14
|
5.3K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix and Taiba enter into License Agreement for DMX-200
|
|
Tym1ng
|
152 |
57K |
23 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
152
|
57K
|
23
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
4 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
4
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
6 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
6
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
2 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
2
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
4 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
4
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
3 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
109
|
29K
|
3
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
4 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
109
|
29K
|
4
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
3 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
109
|
29K
|
3
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
1 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
109
|
29K
|
1
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
3 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
109
|
29K
|
3
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Tym1ng
|
109 |
29K |
0 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
109
|
29K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
Tym1ng
|
239 |
63K |
10 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
239
|
63K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
Tym1ng
|
261 |
71K |
3 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
71K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
19K |
6 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
19K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
19K |
14 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
Tym1ng
|
77 |
19K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Tym1ng
|
66 |
18K |
4 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
Tym1ng
|
66 |
18K |
5 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
66
|
18K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
176 |
52K |
1 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
176
|
52K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
Tym1ng
|
176 |
52K |
5 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
176
|
52K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
Tym1ng
|
93 |
24K |
8 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
93
|
24K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Successfully Passes Efficacy Interim Analysis
|
|
Tym1ng
|
279 |
88K |
9 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
279
|
88K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
Tym1ng
|
63 |
17K |
8 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
17K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
Tym1ng
|
63 |
17K |
11 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
17K
|
11
|
|